5,59 $
2,01 % gestern
Nasdaq, 6. Oktober, 22:00 Uhr
ISIN
US75943R1023
Symbol
RLAY
Berichte

Relay Therapeutics Inc Aktie News

Neutral
Seeking Alpha
26 Tage alt
Relay Therapeutics, Inc. (NASDAQ:RLAY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants Sanjiv Patel - CEO, President & Director Donald Bergstrom - President of Research & Development Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Presentation Sean Laaman...
Positiv
The Motley Fool
etwa ein Monat alt
Precision medicine specialist Relay Therapeutics (RLAY 3.25%) probably didn't want this holiday-shortened trading week to end, since it was quite the stock market star during the period. According to data compiled by S&P Global Market Intelligence, its share price climbed by almost 15%, thanks in no small part to a bullish new analyst note.
Neutral
GlobeNewsWire
etwa ein Monat alt
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September:
Neutral
The Motley Fool
2 Monate alt
Relay (RLAY) Q2 Loss Narrows 41%
Neutral
GlobeNewsWire
2 Monate alt
Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RL...
Positiv
Seeking Alpha
2 Monate alt
Upgraded Relay Therapeutics to a buy after an unjustified valuation decline, maintaining cautious optimism. Recent ASCO data and quarterly updates provide new insights into the evolving investment thesis for RLAY. Pipeline progress and financial health remain central to the company's long-term value proposition and risk profile.
Neutral
GlobeNewsWire
2 Monate alt
CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 7, 2025.
Neutral
GlobeNewsWire
4 Monate alt
CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company's Board of Directors, effective June 9, 2025.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen